Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Skin Diseases and Disorders

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rapamycin for refractory discoid lupus erythematosus.

Dermatologic therapy·2018

Same author

Cerebellar Stroke Occupational Therapy and Physical Therapy Management from Intensive Care Unit to Outpatient: A Case Report.

Cureus·2018

Same author

Subacute cutaneous lupus erythematosus presenting in twins.

Pediatric dermatology·2018

Same author

An atypical syphilis presentation.

Cutis·2017

Same author

Exophytic scalp tumor.

Cutis·2016

Same author

A case of self-healing juvenile cutaneous mucinosis.

Dermatology online journal·2015

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Mycophenolate mofetil in dermatology.

Alissa K Orvis¹, Stanton K Wesson, Thomas S Breza

¹University of Florida College of Medicine, Gainesville, Florida 32611, USA.

Journal of the American Academy of Dermatology

|January 20, 2009

Summary

Mycophenolate mofetil (MMF) is an immunosuppressant showing promise for inflammatory skin diseases due to its lymphocyte specificity. While its use is limited by research gaps and cost, MMF offers a potentially preferable treatment option for dermatologists.

Related Experiment Videos

Last Updated: Jun 26, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid (MPA).
MMF was initially used in transplantation and is now explored off-label for dermatologic conditions.
Its lymphocyte-specific action offers a potentially reduced toxicity profile compared to other immunosuppressants.

Purpose of the Study:

To review the history and pharmacology of MMF as an immunosuppressant.
To recognize the potential role of MMF in treating dermatologic conditions.
To identify future research directions for MMF in dermatology.

Main Methods:

Literature review of MMF's use in dermatology.
Analysis of clinical records for MMF treatment outcomes.
Evaluation of MMF's efficacy and safety in various inflammatory skin diseases.

Main Results:

MMF has been used off-label for psoriasis, autoimmune blistering disorders, dermatitides, and connective tissue disorders.
The drug's lymphocyte specificity is a key attribute for its therapeutic appeal.
Current limitations include a lack of randomized controlled trials, potential unknown side effects, and cost.

Conclusions:

Mycophenolate mofetil (MMF) demonstrates potential as a therapeutic option for cutaneous inflammatory diseases.
Further research, including randomized controlled trials, is needed to fully establish its role.
MMF's unique properties may position it as a valuable treatment in dermatology.